Wechselwirkungen · Stivarga
Stivarga 40 mg film-coated tablets. · Abschnitt 4.5 · PDF-Seite 8
HOS-127092 · Präparat HOS-096369
UGT1A1 and UGT1A9 substrates In vitro data indicate that regorafenib as well as its active metabolite M-2 inhibit glucuronidation mediated by UGT1A1 and UGT1A9 whereas M-5 only inhibits UGT1A1 at concentrations which are achieved in vivo at steady state. Administration of regorafenib with a 5-day break prior to administration of irinotecan resulted in an increase of approximately 44% in AUC of SN-38, a substrate of UGT1A1 and an active metabolite of irinotecan. An increase in AUC of irinotecan of approximately 28% was also observed. This indicates that co-administration of regorafenib may increase systemic exposure to UGT1A1 and UGT1A9 substrates.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): irinotecan (HOS-112102)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-03-24T12:26:00Z · SHA-256 188477d5802aa3c29bbcc6435c9e581d56ccf3178a537b51e23d7bce8cf4f8be · Passage 2027cf55300aa6dd931fb41dbef416e5f3f89b2c7af7df6071d8ec94fa4c8ca5 · Zeichen 1776–2431 im Abschnitt